A Long-term Follow-up Study of Patients Who Received MB-105

N/ANot Yet RecruitingNCT07340814

March Biosciences Inc40 enrolled

Overview

This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study

This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Any Patient Treated With MB-105

Interventions

MB-105BIOLOGICAL

This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Received MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements Exclusion Criteria: N/A

Outcomes

Primary Outcomes

Assess long term safety of MB-105 in patients who received MB-105

SAEs

Time frame: 15 Years

Secondary Outcomes

Assess long term efficacy of MB-105 in patients who received MB-105

Time to progression/relapse in those who have not yet relapsed and overall survival

Time frame: 15 Years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.